stockrow
Saturday 7 November 2026
Export ENLV’s income statement to Excel — free account
Enlivex Ltd.
ENLV Healthcare Biotechnology
- EPS
- +5,349.9%
- Free cash flow
- +35.9%
Quarter to June 2026, against a year earlier
1.27
0.00
0.00%
Follow ENLV
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (16) | (3) | (4) | (9) | (12) | (14) | (31) | (29) | (15) | 1,618 | 4,080 | n/m | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (16) | (3) | (4) | (9) | (12) | (14) | (31) | (29) | (15) | 1,236 | 1,236 | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (9,644.56) | — | (289.99) | (260.27) | (215.38) | (194.32) | (405.04) | (375.41) | (175.57) | 6,485.88 | 8,350.47 | n/m | ||||||
| Cash flow | (9,109.41) | (161.12) | (216.51) | (195.04) | (200.49) | (235.46) | (312.29) | (303.91) | (152.14) | (54.68) | 0.00 | (43.4%) | ||||||
| Capex | (10.59) | (9.09) | (31.58) | (5.24) | (18.56) | (21.81) | (105.89) | (1.33) | 0.95 | (0.35) | 0.00 | (31.5%) | ||||||
| Free cash flow | (9,120.00) | (170.21) | (248.08) | (200.28) | (219.05) | (257.28) | (418.19) | (305.25) | (151.19) | (55.03) | 0.00 | (43.3%) | ||||||
| Book value | 5,117.06 | 593.92 | 664.79 | 312.52 | 646.39 | 1,141.46 | 741.08 | 388.68 | 275.89 | 10,157.21 | 3,770.79 | +7.9% | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +68.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (15) | (2) | (3) | (7) | (11) | (18) | (24) | (24) | (13) | (10) | (10) | (4.3%) | |||||
| Capex | 0 | 0 | 0 | 0 | (1) | (2) | (8) | 0 | 0 | 0 | 0 | +15.7% | ||||||
| Free cash flow | (16) | (2) | (4) | (7) | (12) | (19) | (32) | (24) | (13) | (10) | (10) | (4.3%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 9 | 8 | 9 | 10 | 34 | 82 | 46 | 28 | 22 | 1,734 | 3,720 | +80.3% | |||||
| Net debt | (10) | (9) | (10) | (13) | (36) | (79) | (46) | (27) | (23) | (1,738) | (3,730) | +77.6% | ||||||
| Shareholders’ equity | 9 | 8 | 10 | 11 | 35 | 85 | 57 | 30 | 24 | 1,935 | 3,898 | +82.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (102.88) | (31.93) | (47.64) | (65.64) | (40.83) | (21.35) | (38.16) | (55.65) | (46.54) | 104.94 | 127.16 | +207.8 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (191.41) | (149.41) | (664.68) | (2,533.16) | (4.78) | (5.85) | (4.8) pt | ||||||
| ROE | (120.33) | (38.50) | (56.96) | (91.71) | (50.56) | (24.01) | (43.78) | (66.88) | (55.95) | 126.17 | 159.77 | +246.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 12 | 2 | 31 | 37 | 51 | 72 | 78 | 50 | 36 | 34 | — | +12.3% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Enlivex Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SLXN Silexion Therapeutics Corp | $2.2M | — (loss-making) | — | — | n/m | −16.63% (below 0%: shrinking) | — | 0.00% | Compare |
| BRTX Biorestorative Therapies, Inc. | $2.1M | — (loss-making) | — (loss-making) | −7.20% (below 0%: shrinking) | n/m | −35.26% (below 0%: shrinking) | 68.10% | (14,593.53%) | Compare |
| SILO Silo Pharma, Inc. | $2.1M | — (loss-making) | 18.4× | 0.00% | n/m | +39.17% (above 0%: growing) | (15.00%) | 0.00% | Compare |
| PPBT Purple Biotech Ltd. Sponsored ADR | $2.0M | — (loss-making) | — (loss-making) | — | n/m | −62.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| REVB Revelation Biosciences, Inc. | $2.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ENLV Enlivex Ltd. | $2.0M | 0.0× | — | — | n/m | +35.94% (above 0%: growing) | 0.00% | 0.00% | |
| EDVA Splash Beverage Group, Inc. | $1.9M | — (loss-making) | — (loss-making) | −99.57% (below 0%: shrinking) | n/m | −95.72% (below 0%: shrinking) | 42.86% | 0.00% | Compare |
| GNPX GENPREX | $1.7M | — (loss-making) | — | — | n/m | −32.98% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PPCB Propanc Biopharma Inc | $1.7M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $2.0M | — | — | −7.20% | — | −35.27% | 0.00% | 0.00% |